Destiny Pharma
Skip to content
  • About Us
    • Board of Directors
    • Leadership
    • Scientific Advisory Board
    • History
  • Pipeline
    • NTCD-M3 for Clostridioides difficile Infections
    • XF-73 Nasal for Post Surgical Infections
    • XF-73 for Dermal Infections
    • SPOR-COV™ for COVID-19
    • XF Research Programs
  • Target Markets
    • Clostridioides difficile Infections
    • Post Surgical Infections
    • Dermal Infections
    • COVID-19
    • Anti-Microbial Resistance
  • Our Technologies
    • Biotherapeutics
      • NTCD-M3
      • SPOR-COV™
    • XF Platform
  • Business Development
  • News
  • Investors
    • AIM Rule 26
    • Corporate Governance
    • Share Price Information
    • Regulatory News
    • Constitutional Documents
    • Reports & Presentations
    • Advisers / Shareholder Contacts
    • Analyst Coverage
    • Email Alerts
  • Contact
    • Careers
    • Useful Links

Reports & Presentations

Reports and Presentations

Financial reports

2020 Interim Results

2019 Report and Financial Statements

2019 Full Year Results announcement

2019 Interim Results

2018 Report and Financial Statements

2018 Full Year Results announcement

2018 Interim Results

2017 Report and Financial Statements

2017 Full Year Results announcement

2017 Interim Results

2016 Financial Accounts

Documents sent to shareholders

Result of General Meeting dated 26 November 2020

Note to shareholders

Circular to shareholders dated 10 November 2020

Form of Proxy

Open Offer Application Form

Result of 2020 Annual General Meeting

Notice of 2020 Annual General Meeting

Notice of 2019 Annual General Meeting

Notice of 2018 Annual General Meeting

Presentations

Investor Presentation – February 2021

2020 Interim results presentation (17 September 2020)

2019 Full Year results presentation (29 April 2020)

Destiny Pharma

© All rights reserved.

Powered by WordPress

Destiny Pharma plc
Sussex Innovation Centre
Science Park Square
Brighton
BN1 9SB
UK

Tel: +44(0) 1273 704440

Registered Company
No. 3167025
About Us
Pipeline
Target Markets
Our Technologies
Business Development
News
Investors
Contact
Terms of Use
Privacy Statement